HURAHIGH SIGNALFINANCIAL10-K

HURA shows severe cash burn deterioration with operating cash flow worsening by 88% to -$27.6M while cash reserves plummeted 71% to $3.6M, creating potential liquidity concerns despite completing a major merger.

The company faces a critical cash runway issue as it burns through nearly $28M annually while holding only $3.6M in cash, suggesting immediate funding needs. The 45% increase in shares outstanding (likely from the Kineta merger) diluted existing shareholders significantly, though the merger appears to have added some asset value and reduced debt burden.

Comparing 2026-03-31 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

HURA's financial profile deteriorated sharply with operating cash flow nearly doubling to -$27.6M while cash reserves fell 71% to $3.6M, creating immediate liquidity concerns. The company significantly increased R&D spending by 54% to $20.5M and saw net losses widen 39% to -$30.1M, though it successfully reduced debt by 96% and increased stockholders' equity by 43% through the merger. The overall picture signals a company investing heavily in R&D following its merger but facing critical near-term funding needs given the severe cash burn rate relative to available liquidity.

FINANCIAL STATEMENT CHANGES
Total Debt
Balance Sheet
-96%
$28K$1K

Debt reduced 96% — deleveraging strengthens balance sheet and reduces financial risk.

Operating Cash Flow
Cash Flow
-87.6%
-$14.7M-$27.6M

Operating cash flow fell 87.6% — earnings quality concerns; investigate working capital changes and non-cash items.

Interest Expense
P&L
-84.9%
$4.1M$625K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Current Assets
Balance Sheet
-76.4%
$19.6M$4.6M

Current assets declined 76.4% — monitor working capital adequacy and short-term liquidity.

Cash & Equivalents
Balance Sheet
-71.4%
$12.7M$3.6M

Cash declined 71.4% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

R&D Expense
P&L
+54%
$13.3M$20.5M

R&D investment increased 54% — signals commitment to future product development, though near-term margin impact.

Stockholders Equity
Balance Sheet
+43.4%
$14.6M$20.9M

Equity base grew 43.4% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Net Income
P&L
-38.6%
-$21.7M-$30.1M

Net income declined 38.6% — review whether driven by operations, interest costs, or non-recurring items.

Total Assets
Balance Sheet
+37%
$20.0M$27.4M

Asset base grew 37% — expansion through organic growth, acquisitions, or capital deployment.

Capital Expenditure
Cash Flow
+31.4%
$58K$76K

Capital expenditure jumped 31.4% — major investment cycle underway; assess returns on deployment.

LANGUAGE CHANGES
NEW — 2026-03-31
PRIOR — 2025-03-31
ADDED
As of March 23, 2026, there were 63,578,528 shares of the registrant s common stock outstanding.
The registrant intends to file its proxy statement within 120 days after its fiscal year end.
These factors include, but are not limited to: our ability to raise funds for general corporate purposes and operations, including our research activities and clinical studies; our ability to realize the anticipated benefits of our merger (the Kineta Merger ) with Kineta, Inc.
This Annual Report includes trademarks, service marks and trade names owned by us or other companies.
All trademarks, service marks and trade names included in this Annual Report are the property of their respective owners.
+7 more — sign up free →
REMOVED
As of March 31, 2025, there were 43,680,397 shares of the registrant s common stock outstanding.
Form 10-K Summary 118 Signatures i EXPLANATORY NOTE On October 18, 2024, the Nevada corporation formerly known as Kintara Therapeutics, Inc.
completed its previously announced merger transaction in accordance with the terms of the Agreement and Plan of Merger, dated as of April 2, 2024 (the Kintara Merger Agreement ), by and among Kintara Therapeutics, Inc.
( Legacy TuHURA ), and Kayak Mergeco, Inc., a direct wholly owned subsidiary of Kintara ( Merger Sub ), pursuant to which Merger Sub merged with and into Legacy TuHURA, with Legacy TuHURA surviving as a direct wholly owned subsidiary of Kintara and the surviving corporation of the merger (the Kintara Merger ).
Additionally, as a result of the Kintara Merger, Kintara changed its name from Kintara Therapeutics, Inc.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →